TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02831595

Intervention type: DEVICE
Intervention: GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis
Study: NCT02938286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser, 2.5 mJ, 5% density
Description: Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser, 2.5 mJ, 15% density
Description: Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG laser, 9 mJ, 5% density
Description: Pretreatment at 9 mJ and 5% density.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Er:YAG laser, 9 mJ, 15% density
Description: Pretreatment at 9 mJ and 15% density.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus at 50 mJ/microbeam and 5% density

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus at 50 mJ/microbeam and 5% density

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus at 50 mJ/microbeam and 5% density

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser, 50 mJ, 5% density
Description: Pain stimulus at 50 mJ/microbeam and 5% density

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES
Description: Topical application at test region I-IV under occlusion for 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES
Description: Topical application at test region I-IV under occlusion for 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES
Description: Topical application at test region I-IV under occlusion for 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHES
Description: Topical application at test region I-IV under occlusion for 15 minutes
Study: NCT00806884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Musculoskeletal Treatment
Description: Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group measurements
Description: None other than control group measurements
Study: NCT01529372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PARADISE percutaneous renal denervation
Description: Intravascular ultrasound emission
Study: NCT00674765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel
Description: 400 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg/day
Study: NCT02883985

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 6 Gy/ fraction
Description: All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.~In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment.
Study: NCT03469089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.58
Description: Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.58
Description: Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.31
Description: Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil tablet 100 mg placed in a capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ketamine
Description: 0.9 % NaCl infusion solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for modafinil
Description: Placebo capsule for modafinil capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for modafinil
Description: Placebo capsule for modafinil capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for modafinil
Description: Placebo capsule for modafinil capsule
Study: NCT01002586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii-Fit intervention
Description: Half hour daily, five days a week, for 8 weeks
Study: NCT03387449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bimanual Arm Training
Description: Device-based bimanual-to-unimanual training will be provided with the Bimanual Arm Trainer (BAT, Mirrored Motion Works, NC). The device provides bimanual-to-unimanual training of simultaneous shoulder external rotation and elbow extension, and independent training of pronation-supination and grasp and release of each hand. Range of motion and speed are recorded during training and feedback and motivation are provided through age-appropriate gaming modules.
Study: NCT02501980

Intervention type: BIOLOGICAL
Intervention: Biomarker testing and Ultrasonography
Study: NCT02381912

Intervention type: OTHER
Intervention: EORTC QLQ-C30 and EORTC BLS-24 questionnaire
Description: Questionnaires answered at baseline and 4 months follow up.
Study: NCT01002586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercise program
Description: walking exercise program
Study: NCT03118609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Understanding Needs Survey
Description: 2-hour Focus Group~Mailed or E-mailed Survey
Study: NCT01543945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg iv before induction for high and extremely high risk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg iv before ended surgery 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 4 mg iv before ended surgery 30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate
Description: 1 mg/kg iv before ended surgery 30 min
Study: NCT02869308

Intervention type: DRUG
Group type: OTHER
Intervention: stannous pyrophosphate
Description: Injection of 1ml Angiocis
Study: NCT03406013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription
Description: Participants receive tailored exercise prescription and tailored diet recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription
Description: Participants receive tailored exercise prescription and tailored diet recommendations
Study: NCT02768675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOADPRO
Description: The Intellirod LOADPRO sensor is a single-use, disposable instrument for the intra-operative measurement of posterior instrumented, spine rod strain.
Study: NCT03880903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline and salbutamol
Description: patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours
Study: NCT03406013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology
Description: Participants receive motivational text messages and can electronically log and track their exercise and diet habits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology
Description: Participants receive motivational text messages and can electronically log and track their exercise and diet habits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Participants receive access to an exercise and diet coach to provide advice by phone and/or email
Study: NCT04342078

Intervention type: DIETARY_SUPPLEMENT
Intervention: Vitamin D
Description: To investigate the effect of one year vitamin D supplementation in preterm born adults (4000 IU = 100 micrograms a day if serum concentration is \< 30 nmol/l, 2000 IU = 50 micrograms a day if 30-50 nmol/l and 1000 IU = 25 micrograms a day if \> 50-80 nmol/l, and no additional supplement if \> 80 nmol/l) on health outcomes (bones, teeth, muscles, heart, lungs) . The target level of vitamin D concentration by every 4 months interval is 80 - 120 nmol/l .(Preterm Adult group)
Study: NCT03106974

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orotracheal intubation Macintosh Laryngoscope
Description: orotracheal intubation (OTI) after induction of anesthesia and complete relaxation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orotracheal intubation Totaltrack VLM
Description: orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
Study: NCT01848119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Study: NCT01359202

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rfVIIa
Description: 80ug/kg IV bolus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard saline solution
Description: Saline
Study: NCT00599755

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Comparator: CT or MRI and FDG-PET
Description: Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin or Gemcitabine and Carboplatin
Description: Gemcitabine administered intravenously at a dose of 1000-1250 mg/m\^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m\^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
Study: NCT04909658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Matrix
Description: The ACT protocol group performs exercises to improve the psychological well-being of parents. The matrix is an ACT protocol that is usually presented visually to patients and consists of two intersecting lines that make up four quadrants, which provide a point of view on one's psychological actions and experiences. The vertical line is the line of experience, the upper part corresponds to the experience of life linked to the five senses - sight, hearing, taste, smell and touch - (experience of the five senses), the lower part refers to the experiences internal as thoughts and feelings (internal/mental experience). The horizontal line is the behavior line, the left side concerns the actions that perform the function of moving us away from experiences, emotions, unwanted thoughts (experiential avoid-ance), the right side indicates the actions we take to get closer and go towards our values (committed action).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PT Protocol
Description: The PT protocol group received behavioral tasks related to child management. Parent training interventions carried out in groups can be a good solution to modify parent behavior by providing social support and new coping strategies. The intervention includes 24 weekly meetings lasting 90 minutes each. The total intervention is six months.
Study: NCT01023672

Intervention type: DRUG
Group type: OTHER
Intervention: Armodafinil
Description: 150-250 mg armodafinil by mouth daily
Study: NCT04264364

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Bariatric surgical intervention

Intervention type: PROCEDURE
Intervention: Endoscopic sleeve gastroplasty
Description: Endoscopic bariatric procedure
Study: NCT05332652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trancranial magnetic stimulation
Description: A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trancranial magnetic stimulation
Description: A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: trancranial magnetic stimulation
Description: A trained research staff or physician will perform tDCS to the subject. Direct current will be delivered by a battery-operated, constant current stimulator, through 2 rubber electrodes embedded in a pair of saline-soaked sponge bag. Stimulation intensity will be ramped up to 1 mA over 30 seconds and maintain at 1 mA for 20 minutes, and then ramped down to 0 mA over 30 seconds.
Study: NCT03880903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline and salbutamol
Description: patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours
Study: NCT03758742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Fruit Diet
Description: Participants will consume a diet rich in whole fruit. During Phase I (Weeks 1-4; supervised controlled feeding), participants will gradually increase the amount of whole fruit they consume, eventually reaching 50% of calories from whole fruit. In Phase II (Week 5-12; supervised controlled feeding), participants will consume a whole fruit-rich, eucaloric diet that provides 50% of calories in the form of whole fruit. The non-fruit portion of the diet will be styled as a Mediterranean Diet. Participants will be required to approximately keep their weight stable during Phases I and II. In the Follow-Up Phase (Months 4-12; free-living), participants will be instructed to continue consuming at least one-third of their diet as whole fruit and to make healthy food choices.
Study: NCT04081948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (Group E)
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham block group (Group S)
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.
Study: NCT00881946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK21110183
Description: Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
Study: NCT02791620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a nanofractional radiofrequency device
Description: A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
Study: NCT02818595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroencephalogram (HR-EEG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroencephalogram (HR-EEG)
Study: NCT02869308

Intervention type: DRUG
Group type: OTHER
Intervention: Technetium-99m
Description: Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection

Intervention type: DEVICE
Group type: OTHER
Intervention: E-CAM Camera
Description: Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
Study: NCT05311267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation training
Description: Subject is asked to observe videos with motor contents
Study: NCT03105349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elbasvir/grazoprevir
Description: 16 weeks treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 16 weeks treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 16 weeks treatment
Study: NCT02869308

Intervention type: DEVICE
Group type: OTHER
Intervention: CZT Semiconductor Camera (D-SPECT)
Description: Acquisition of images of angioscintigraphy with D-SPECT camera
Study: NCT02282137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
Study: NCT00330135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Description: Sodium hyaluronate 2.5 ml - 1 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: placebo injection - 1 injection
Study: NCT04552184

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GPOEM
Description: gastric per oral endoscopic pyloromyotomy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM Procedure
Description: intrapyloric injection of saline solution
Study: NCT02818595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infra Red Spectroscopy (NIRS)
Study: NCT02605915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
Study: NCT05014997

Intervention type: OTHER
Intervention: no intervention
Description: this study was designed as retrospective observational study
Study: NCT01052558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent Inject (GTS400)
Description: Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Surgery
Description: Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
Study: NCT04717505

Intervention type: OTHER
Intervention: Gait Assessments
Description: 10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device.

Intervention type: OTHER
Intervention: Gait Assessments
Description: 10 Meter Walking Test: It is applied by walking at a normal walking speed (like walking in a shopping mall) without any assistance at a marked distance of 10 meters.~1- Evaluation of walking under single task conditions is done with the 10 Meter Walk Test and without any cognitive or motor second task. Evaluation of walking under dual task conditions is applied in two different ways: 2-adding a cognitive task to the walking motor task (motor + cognitive dual task) 3-adding one more motor task to the walking motor task (motor + motor dual task). While performing dual tasks, the time-distance (walking speed, cadence, stride length) characteristics of the gait are recorded using with wearable gait device.

Intervention type: OTHER
Intervention: Arthritis Impact Measurement Scales 2
Description: It is a multidimensional, disease-specific, self-administered questionnaire designed to measure health status outcomes in patients with arthritis.
Study: NCT02404350

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab
Description: Anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab
Description: Anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Anti IL-17a monoclonal antibody
Study: NCT04717505

Intervention type: OTHER
Intervention: Visual Analogue Scale
Description: The Visual Analogue Scale is a reliable and easily applicable scale used to measure the pain intensity of patients, accepted in the world literature.
Study: NCT02404350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Anti IL-17a monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Anti IL-17a monoclonal antibody